

# Fotios V Michelis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8596497/publications.pdf>

Version: 2024-02-01

78  
papers

832  
citations

516710

16  
h-index

642732

23  
g-index

78  
all docs

78  
docs citations

78  
times ranked

1098  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
3	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 50.e1-50.e8.	1.2	11
4	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , 2022, 108, 61-72.	2.2	9
5	Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. <i>European Journal of Haematology</i> , 2022, 108, 430-436.	2.2	2
6	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	1.2	6
7	Anti-thymocyte Globulin and Post-transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen A and B mismatched donors. <i>European Journal of Haematology</i> , 2022, 108, 288-297.	2.2	4
8	The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. <i>EJHaem</i> , 2022, 3, 873-884.	1.0	2
9	Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	2
10	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2021, 144, 66-73.	1.4	11
11	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 60-69.	2.4	26
12	Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 241-249.	2.2	4
13	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , 2021, 56, 689-691.	2.4	1
14	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2021, 106, 32-39.	2.2	16
15	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021, 106, 158-164.	2.2	2
16	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. <i>American Journal of Hematology</i> , 2021, 96, 179-187.	4.1	23
17	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 302-310.	0.9	4
18	Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	3

#	ARTICLE	IF	CITATIONS
19	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 1311-1319.	1.8	2
20	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	2.4	10
21	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	1.2	11
22	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. <i>European Journal of Haematology</i> , 2021, 107, 354-363.	2.2	1
23	Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e559-e568.	0.4	3
24	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , 2021, 107, 517-528.	2.2	2
25	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 600.e1-600.e8.	1.2	5
26	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	1.3	12
27	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , 2021, 106, 508-519.	2.2	1
28	Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	2
29	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	0
30	My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 867-872.	2.4	9
31	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 104, 36-45.	2.2	7
32	Allogeneic stem cell transplant in myelodysplastic syndrome—factors impacting survival. <i>European Journal of Haematology</i> , 2020, 104, 116-124.	2.2	5
33	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1377-1387.	1.8	15
34	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1511-1519.	2.0	6
35	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 105, 24-29.	2.2	5
36	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1773-1783.	2.4	35

#	ARTICLE	IF	CITATIONS
37	Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib. Blood, 2020, 136, 17-18.	1.4	0
38	Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission. Blood, 2020, 136, 36-37.	1.4	0
39	Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment. Blood, 2020, 136, 1-2.	1.4	1
40	ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Ā and HLA-B Mismatched Unrelated Donors. Blood, 2020, 136, 31-31.	1.4	0
41	Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre. Blood, 2020, 136, 23-24.	1.4	1
42	Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study. Blood, 2020, 136, 18-18.	1.4	1
43	EpsteinĀBarr virus associated postĀtransplant lymphoproliferative disorder mimicking acute graft versus host disease. European Journal of Haematology, 2019, 103, 519-522.	2.2	2
44	ReducedĀintensity conditioning allogeneic transplant with dual TĀcell depletion in myelofibrosis. European Journal of Haematology, 2019, 103, 597-606.	2.2	9
45	Reduced intensity allogeneic stem cell transplant with antiĀthymocyte globulin and postĀtransplant cyclophosphamide in acute myeloid leukemia. European Journal of Haematology, 2019, 103, 510-518.	2.2	19
46	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. European Journal of Haematology, 2019, 103, 483-490.	2.2	10
47	Influence of <i>FLT3ĀTD</i> and <i>NPM1</i> status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. European Journal of Haematology, 2019, 102, 368-374.	2.2	6
48	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. European Journal of Haematology, 2019, 102, 486-493.	2.2	32
49	Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability. Biology of Blood and Marrow Transplantation, 2019, 25, 1158-1163.	2.0	17
50	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. Clinical Hematology International, 2019, 1, 105-113.	1.7	18
51	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. Blood, 2019, 134, 3344-3344.	1.4	0
52	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Blood, 2019, 134, 3299-3299.	1.4	0
53	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. Blood, 2019, 134, 4590-4590.	1.4	0
54	No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. Blood, 2019, 134, 4514-4514.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1901-1905.	2.0	35
56	Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. <i>Bone Marrow Transplantation</i> , 2018, 53, 334-338.	2.4	2
57	Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 361-365.	2.4	28
58	Impact of comorbidities constituting the hematopoietic cell transplant (HCT) comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. <i>European Journal of Haematology</i> , 2018, 100, 198-205.	2.2	18
59	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. <i>European Respiratory Journal</i> , 2018, 51, 1702330.	6.7	11
60	Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 366-372.	2.0	30
61	Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience. <i>European Journal of Haematology</i> , 2018, 100, 308-314.	2.2	13
62	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <i>Annals of Hematology</i> , 2018, 97, 1975-1985.	1.8	7
63	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2259-2264.	2.0	66
64	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	4.1	14
65	Progressive Multifocal Leukoencephalopathy due to John Cunningham (JC) virus following Allogeneic Haematopoietic Cell Transplantation. <i>Antiviral Therapy</i> , 2017, 22, 721-725.	1.0	5
66	Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data. <i>European Journal of Haematology</i> , 2017, 99, 160-168.	2.2	6
67	Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1. <i>European Journal of Haematology</i> , 2017, 99, 234-239.	2.2	15
68	Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 945-951.	2.0	9
69	Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2270-2275.	2.0	17
70	Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants. <i>Blood</i> , 2016, 128, 3430-3430.	1.4	1
71	Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, 392-399.	4.1	17
72	A case report and literature review of chronic graft-versus-host disease manifesting as polymyositis. <i>International Journal of Hematology</i> , 2015, 102, 144-146.	1.6	9

#	ARTICLE	IF	CITATIONS
73	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e73-e81.	0.4	11
74	Benefit of Allogeneic Transplantation in Patients Age $\geq 60$ Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 474-479.	2.0	21
75	Acute hemolysis after intravenous immunoglobulin amid host factors of $\langle \text{sc} \rangle \text{ABO} \langle / \text{sc} \rangle$ -mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. <i>Transfusion</i> , 2014, 54, 681-690.	1.6	31
76	Early lymphocyte recovery at 28 days post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. <i>European Journal of Haematology</i> , 2014, 93, 273-280.	2.2	21
77	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1751-1757.	2.0	15
78	Effects of the Flavonoid Pilloin Isolated from <i>Marrubium cylleneum</i> on Mitogen-Induced Lymphocyte Transformation. <i>Pharmaceutical Biology</i> , 2002, 40, 245-248.	2.9	17